疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2014年
7期
686-689,693
,共5页
王光辉%许阳%刘勇谋%张金萍
王光輝%許暘%劉勇謀%張金萍
왕광휘%허양%류용모%장금평
非小细胞肺癌,晚期%表皮生长因子受体酪氨酸激酶抑制剂%治疗
非小細胞肺癌,晚期%錶皮生長因子受體酪氨痠激酶抑製劑%治療
비소세포폐암,만기%표피생장인자수체락안산격매억제제%치료
Non-small cea lung cancer,advanced%Epidermal growth factor receptor tyrosine kinase inhibitors%Treatment
目的:评价表皮生长因子受体酪氨酸激酶抑制剂( EGFRT-TKI)治疗晚期非小细胞肺癌( NSCLC)的疗效及安全性。方法晚期NSCLC患者160例使用EGFR-TKI吉非替尼或厄洛替尼治疗,其中77例(48.1%)为一线治疗组,83例(51.9%)为二线治疗组。观测其临床特征、治疗效果及生存时间,并对药物安全性进行评估。结果EGFR-TKI治疗总有效率为33.8%(54/160),疾病控制率为74.4%(119/160)。无进展中位生存时间为9.8个月,中位生存时间为14.5个月,1年生存率为55%。 Logistic多因素回归分析显示,病理类型、皮疹情况和血清CEA变化与有效率相关( P均<0.05);病理类型、吸烟史、皮疹情况、血清CEA变化与疾病控制率相关( P均<0.05);病理类型为影响无进展生存的独立因素,PS评分为影响生存的独立因素。一线治疗、二线治疗疗效相当。药物不良反应主要表现为皮疹和轻度腹泻。结论 EGFR-TKI治疗晚期NSCLC安全有效。
目的:評價錶皮生長因子受體酪氨痠激酶抑製劑( EGFRT-TKI)治療晚期非小細胞肺癌( NSCLC)的療效及安全性。方法晚期NSCLC患者160例使用EGFR-TKI吉非替尼或阨洛替尼治療,其中77例(48.1%)為一線治療組,83例(51.9%)為二線治療組。觀測其臨床特徵、治療效果及生存時間,併對藥物安全性進行評估。結果EGFR-TKI治療總有效率為33.8%(54/160),疾病控製率為74.4%(119/160)。無進展中位生存時間為9.8箇月,中位生存時間為14.5箇月,1年生存率為55%。 Logistic多因素迴歸分析顯示,病理類型、皮疹情況和血清CEA變化與有效率相關( P均<0.05);病理類型、吸煙史、皮疹情況、血清CEA變化與疾病控製率相關( P均<0.05);病理類型為影響無進展生存的獨立因素,PS評分為影響生存的獨立因素。一線治療、二線治療療效相噹。藥物不良反應主要錶現為皮疹和輕度腹瀉。結論 EGFR-TKI治療晚期NSCLC安全有效。
목적:평개표피생장인자수체락안산격매억제제( EGFRT-TKI)치료만기비소세포폐암( NSCLC)적료효급안전성。방법만기NSCLC환자160례사용EGFR-TKI길비체니혹액락체니치료,기중77례(48.1%)위일선치료조,83례(51.9%)위이선치료조。관측기림상특정、치료효과급생존시간,병대약물안전성진행평고。결과EGFR-TKI치료총유효솔위33.8%(54/160),질병공제솔위74.4%(119/160)。무진전중위생존시간위9.8개월,중위생존시간위14.5개월,1년생존솔위55%。 Logistic다인소회귀분석현시,병리류형、피진정황화혈청CEA변화여유효솔상관( P균<0.05);병리류형、흡연사、피진정황、혈청CEA변화여질병공제솔상관( P균<0.05);병리류형위영향무진전생존적독립인소,PS평분위영향생존적독립인소。일선치료、이선치료료효상당。약물불량반응주요표현위피진화경도복사。결론 EGFR-TKI치료만기NSCLC안전유효。
Objective To investigate the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibi -tor (EGFRT-TKI) in treatment of advanced non-small cell lung cancer (NSCLC).Methods Patients with advanced NSCLCof 160 cases underwent EGFR-TKI gefitinib or erlotinib treatmen,t of which 77 cases (48.1%) as first-line treatment group,83 cases (51.9 %) as second-line treatment group.The clinical features, treatment outcome and survival time were observed ,and evaluated the drug safety.Results The total effective rate of EGFR-TKI was 33.8% (54/160), disease control rate was74.4% (119/160).The median survival time of no progress was 9.8 months, the median survival time was 14.5 months, 1year survival rate was 55%.Multivariate Logistic regression analysis showed,pathological type,skin rash and changes of serumCEA associated with the effective rate ( P <0.05); pathological type, smoking history, skin rash, changes of serum CEAwere correlated with disease control rate ( P <0.05); pathological types were independent factors affecting the progressionfree surviva,l PS was an independent prognostic factors for survival .The first-line and second-line treatment efficacy were similar.Adverse drug reactions including rash and mild diarrhea .Concluis on It demonstrated that the EGFR-TKI is safety andeffective in treatment of advanced NSCLC .